Cardiomyopathy

3 trials 2 recruiting MedDRA PT
3 Registered trials
2 Recruiting
3 Unique sponsors
3 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 4
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
siRNA 1 substance
Phase III: 1 Phase II: 3

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

1 trial
  • Alnylam Pharmaceuticals Inc. Commercial
    NUCRESIRAN
    2024-519917-72-00 18 countries 2025 n=742
    Recruiting

Phase II

3 trials
  • Imbria Pharmaceuticals Inc. Commercial
    NINERAFAXSTAT TRIHYDROCHLORIDE MONOHYDRATE
    2024-515125-28-00 9 countries 2025 n=130
    Recruiting
  • Red Andaluza De Diseno Y Traslacion De Terapias Avanzadas Fundacion Publica Andaluza Progreso Y Salud Academic
    AUTOLOGOUS BONE MARROW-DERIVED ADULT MONONUCLEAR CELLS, NOT EXPANDED
    2024-516594-71-01 1 country 2013 n=51
    Ended
  • Red Andaluza De Diseno Y Traslacion De Terapias Avanzadas Fundacion Publica Andaluza Progreso Y Salud Academic
    AUTOLOGOUS BONE MARROW-DERIVED ADULT MONONUCLEAR CELLS, NOT EXPANDED
    2024-516594-71-01 1 country 2013 n=51
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Red Andaluza De Diseno Y Traslacion De Terapias Avanzadas Fundacion Publica Andaluza Progreso Y Salud Academic 2 Phase II 0
Imbria Pharmaceuticals Inc. Commercial 1 Phase II 1
Alnylam Pharmaceuticals Inc. Commercial 1 Phase III 1
New trials by year
2025
2
← All indication landscapes